European Medicines Agency (EMA) Accepts Marketing Authorisation Application for Prestige BioPharma’s Trastuzumab Biosimilar HD201 for Review

European Medicines Agency (EMA) Accepts Marketing Authorisation Application for Prestige BioPharma’s Trastuzumab Biosimilar HD201 for Review

Tuesday, May 28, 2019 | DrugName : trastuzumab biosimilar

Prestige BioPharma (herein, Prestige) announced that European Medicines Agency (EMA) has validated and accepted for review the Marketing Authorization Application (MAA) for its trastuzumab biosimilar HD201 (Tuznue®) on 23 May 2019.

[sg_popup id=”2993″ event=”inherit”][/sg_popup]HD201 is Prestige’s lead development candidate biosimilar to Herceptin (trastuzumab), which is indicated for the treatment of adult patients with HER2-overexpressing breast cancer as well as HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma. Accordingly, if authorized by the EMA, HD201 (Prestige) would take part in the race along with Herzuma (Celltrion), Kanjinti (Amgen), Ontruzant (Merck Sharp & Dohme), and Trazimera (Pfizer) to seize the EU market as one of the comparable biosimilars, which is currently dominated by Herceptin (Roche).

Furthermore, the positive top-line results from the Phase I / Phase III global clinical trial of HD201 confirm that HD201 is exceptionally biosimilar to Herceptin in terms of clinical response and PK, in addition to a comparable safety profile to the range previously observed in other trastuzumab biosimilar trials.

Dr Lisa S. Park, Chief Executive Officer of Prestige, commented: “We are very pleased that EMA has initiated the review of the HD201 Marketing Authorisation Application. It is a major step in our endeavor to become a global player focussing on biosimilars and innovative biologics. Our development approach has proven to be highly efficient with regard to trial performance, demonstrating exceptional similarity, and dossier filing.”

HD201 is Prestige’s first biosimilar to receive a positive Committee for Medicinal Products for Human Use (CHMP) opinion for marketing authorization from the EMA. Based on this achievement, Prestige will continue to move forward with other 8 biosimilars and innovative biologics in its portfolio, which are currently at different stages of development, from nonclinical development to advanced clinical stages.

Key Facts

    •  News Category

      Other Product News 
      Product Approvals 
      Product Development 
      Regulatory 

    Thankfully, some modern, effective and easily available erection-enhancing medicines are order uk viagra available to normalize male sexual health. A person can my link buying levitra from canada lead to alcohol addiction maybe because of depression, stress, genetic predisposition, emotional health and social environmental factors. Storing it in a dry place at around 20 to 25 degrees Celsius is favored a lot and are very essential in a levitra 10 mg person s life. The purpose of nutrition response testing is to determine female viagra in india cute-n-tiny.com the underlying causes of ill health.

    •  Company

      Prestige BioPharma Pte Ltd

    •  Country

      Asia-Pacific > Singapore 
      Europe > United Kingdom 

.

Leave a Reply

Your email address will not be published. Required fields are marked *

+ 4 = 7